RxDoctor Payments DataLook up a doctor →

Anita Palandri, NP

Nurse Practitioner · Phoenix, AZNPI 1851840870

Payments from drug & device makers

$19,531in general payments, 2019–2025

Across 846 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Merck$1K
  • AstraZeneca$1K
  • Pfizer$960
  • Lilly USA, LLC$857
  • Bristol Myers Squibb$850
  • plus $13K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis71$1,224
Merck50$1,101
AstraZeneca(2 entities)47$1,032
Pfizer47$960
Lilly USA, LLC32$857
Bristol Myers Squibb56$850
Daiichi Sankyo Inc.33$779
CTI Biopharma Corp.3$747
Seagen Inc.28$716
Exelixis Inc.7$702
E.r. Squibb & Sons, L.L.C.45$675
Incyte Corporation24$599
Karyopharm Therapeutics Inc.10$596
Sanofi28$593
Genentech USA, Inc.23$582
Amgen24$512
Astellas Pharma US Inc15$475
Johnson & Johnson23$466
AbbVie22$461
Gilead(2 entities)19$396
Genmab U.S., Inc.13$357
Bayer17$352
EMD Serono, Inc.13$341
Eisai Inc.16$328
Tersera Therapeutics LLC12$288
Puma Biotechnology, Inc.11$231
Pharmacyclics LLC, An Abbvie Company8$208
Jazz Pharmaceuticals Inc.8$191
Array Biopharma Inc12$185
Ipsen Biopharmaceuticals, Inc10$180
Stemline Therapeutics Inc.7$157
GSK7$143
Sobi, Inc9$136
Rigel Pharmaceuticals, Inc.6$132
Takeda Pharmaceuticals U.S.A., Inc.6$130
Pharmacosmos Therapeutics Inc.5$115
Blueprint Medicines Corporation5$115
Springworks Therapeutics, Inc.4$111
Regeneron Healthcare Solutions, Inc.4$111
ADC Therapeutics America, Inc.5$108
Boehringer Ingelheim4$103
Sumitomo Pharma America, Inc.4$96
AVEO Pharmaceuticals, Inc.5$90
Adaptive Biotechnologies Corporation4$88
Beigene USA, Inc.4$70
Myovant Sciences Inc.4$69
Sanofi-aventis U.S. LLC1$67
Deciphera Pharmaceuticals Inc.3$61
Servier Pharmaceuticals LLC3$59
Morphosys, US Inc.3$50
Kyowa Kirin, Inc.2$47
Progenics Pharmaceuticals, Inc.2$42
Recordati_rare_diseases_inc.2$42
AMAG Pharmaceuticals, Inc.2$40
G1 Therapeutics, Inc.2$38
Sun Pharmaceutical Industries Inc.1$37
Mirati Therapeutics, Inc.2$37
EUSA Pharma (US) LLC2$35
Beone Medicines USA, Inc.1$33
Tempus AI, Inc1$27

How this compares

$19,531 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona →

Medicare billing

Part B allowed, 2024
$567,311
Medicare patients
160
Services billed
25,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Phoenix

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →